Merck (MRK)
$93.00
0.15 (0.16%)
MRK Stock Quote Delayed 30 Minutes
Pharma, Tech Drive the Dow: Monday’s IP Market Recap
markets managed to start out the new month on a up note, as pharmaceuticals and technology companies shined during a broad-based rally
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$92.25
Market Cap
233.03B
PE Ratio
13.81
EPS
6.7363
Volume (Avg. Vol.)
12.30M
Day's Range
$91.78 - $93.21
52-Week Range
$81.04 - $132.70
Dividend & Yield
$3.12 (3.35%)
MRK Stock Predictions, Articles, and Merck News
Healthcare Stocks: The Market’s Latest Untouchable Sector
The healthcare sector has delivered outstanding year-to-date returns, but investors need to be aware how much of the performance is the result of macro trends.
Apple Is a Strong Buy But Keep an Eye on The Price
Apple's fall from grace happens because its a non-correlated stock that doesn't behave in step with the greater markets. Now may be a good time to get back in.
An HIV ‘Cure’? Let’s Not Overstate the Success
Merck, J&J and others won't be dropping their research to recreate the success seen in the early treatment of an HIV-positive child.
Newborn Cured of HIV
A little girl in Mississippi, who was born infected with HIV, was apparently cured of the disease after receiving a three drug cocktail shortly after birth.
Should I Buy Merck? 3 Pros, 3 Cons
Merck is in the midst of a prolonged downtrend after hitting multiyear highs in 2012. Should you get in, or keep avoiding the Big Pharma stock?
3 Semiconductor Stocks to Buy Now
The grades of three Semiconductor stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.
2 Newer Names for Retirement Income
If you’re a retiree who needs income for living expenses, consider these new closed-end funds yielding more than 7%.
Top 10 Dow Dividend Stocks for February
Income investors could do a lot worse than buying into these venerable blue chips -- especially the stock that continues to hold the crown.
Fourth-Quarter Earnings: Halftime Update
What should we expect after a surprisingly upbeat first half of Q4's earnings season? Unfortunately, nothing as good as what we've seen already.
3 Healthcare Stocks About to Receive a Booster Shot
Despite the impressive performance of healthcare stocks as a whole, many aren't getting much analyst love. But these three will -- and when they do, look out!
4 Semiconductor Stocks to Buy Now
The grades of four Semiconductor stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
5 Pharmaceutical Stocks to Buy Now
This week, five Pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
Flu Season: Where Investors Can Find Relief
This year's flu looks particularly troublesome, but that's good new for the many companies that benefit from flu sufferers' ills. Here's a look at some of them.
9 Stock Charts to Watch in January
If you're looking for trading ideas to capitalize on volatility at the start of 2013, these stock charts could signal opportunity.
5 Mutual Funds to Buy for 2013
Simplify at least part of your portfolio by picking some solid mutual funds in the coming year. Here are five promising names to consider.
Which Abbott Is the One to Own Post-Split?
Both offer good prospects, but if you can choose just one, AbbVie -- which is the device and diagnostics side -- looks a tad more promising than the pharma arm.
From the Experts: 4 Stocks to Hold Forever
Forever may be a long time, but these stocks picked by our InvestorPlace experts are tried-and-true investments that you can count on for the long haul.
Top 10 Dow Dividend Stocks for December
Income investors could do a lot worse than buying into these venerable blue chips, but some only have great yields thanks to a not-so-hot year.
Big Pharma: 2012-13’s Flu Vaccine Field
Here's a look at the various big pharma stocks that could see a bump from an early start to this year's flu season.
Effective Alzheimer’s Drugs May Be Just Three Years Away
New research, both by scientists and the big drug companies, is leading to increased hope for sufferers of Alzheimer's disease.
